Market Overview

Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers

Related JUNO
9 Notable Biotechs Presenting At This Year's ASH Meeting
4 Biggest Technical Levels To Watch Friday Morning
Juno Clinical Trial Updates Continue To Impress (Seeking Alpha)
Related KITE
As Gilead's Outlook Dims, Argus Downgrades
Life (Science) Lessons: The Hows And Whos To Play Biotech
Gilead: Buying New Growth (Seeking Alpha)

Juno Therapeutics Inc (NASDAQ: JUNO) gained nearly 50 percent to $69.16 after the bell before falling off slightly. The company obtained regulatory approval for an investigational new drug application concerning its B cell non-Hodgkin lymphoma treatment.

Kite Pharma Inc (NASDAQ: KITE) rose 11 percent to $65.50. The company didn't issue news but is developing a gene therapy platform that has been compared with Juno's technology.

Eleven Biotherapeutics Inc (NASDAQ: EBIO) picked up 4.6 percent, trading at $2.95 after hours. The company didn't issue news.

Assured Guaranty Ltd. (NYSE: AGO) bounced up nearly 3 percent in late trading to $24.44. The company, which provides credit protection products to U.S. and international public finance, was off more than 13 percent before the bell Monday.

Intrexon Corp (NYSE: XON) rose 2.7 percent to $48.50. The company closed down earlier by 2.2 percent and didn't issue news.

Apollo Education Group Inc (NASDAQ: APOL) dropped 5 percent to $14.75 in late trading. The education services provider posted third quarter results after the bell Monday. Ltd (NYSE: WBAI) fell nearly 2.8 percent to $24.75 in the extended session. Earlier Monday, the online sports lottery service provider in China completed a private placement of 63.5 million shares at the equivalent of $19.50 per American depositary receipt.

Xunlei Ltd (NASDAQ: XNET) declined 2 percent to $11.25. The shares closed down more than 5 percent earlier. Xunlei, which provides an Internet platform in China, didn't issue news.

Hewlett-Packard Company (NYSE: HPQ) was off by 1.8 percent to $29.44 after the bell. The shares closed down by 1.9 percent and reportedly had its target price cut by Jefferies.

Aratana Therapeutics Inc (NASDAQ: PETX) dipped 1 percent to $14.70. The veterinary medicine company closed up earlier by more than 10 percent after it announced positive results from a study of its drug for appetite stimulation for dogs.

Posted-In: News After-Hours Center Movers


Related Articles (APOL + AGO)

View Comments and Join the Discussion!

Partner Center